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The persistent course and enduring disability commonly
associated with psychosis make imperative the continuing devel-
opment and evaluation of new treatments.1–5 Systematic reviews
have concluded that combining medication with psychological
interventions, specifically cognitive–behavioural therapy (CBT)
and family intervention, improves clinical outcomes.6–9 The
evidence for relapse reduction is robust for family interven-
tion,6,9–11 with reductions around 20%.12 However, its imple-
mentation in routine service settings is poor and it is
inapplicable for the many patients without close carers. There is
consistent evidence that CBT reduces psychotic symptoms in
people with medication-resistant symptoms,6–9 and early indica-
tions that it may also reduce relapse13 and emotional distress.14
The population for which the evidence for the effectiveness of
CBT is most robust comprises patients in a stable phase of illness
selected by referrers for the presence of persistent, medication-un-
responsive and distressing positive symptoms. However, even for
positive symptom reduction, effect sizes were small, at only 0.35
and 0.37 in recent meta-analyses.8,15 Tarrier & Wykes15 have
queried methodological standards in CBT studies. Nevertheless,
recent guidelines, particularly those of the UK National Institute
for Health and Clinical Excellence (NICE),16 have recommended
that both CBT and family intervention should be made more
widely available and that the effectiveness of CBT for relapse
should be further researched.
The trial reported here was motivated by the need for
methodologically secure information on the effectiveness of
CBT, particularly in relation to relapse reduction. This required
inclusion of patients with a recent relapse of established non-
affective psychosis who were at risk of further relapse, rather than
including patients more traditionally treated with CBT, namely
those in a stable illness phase with distressing symptoms. We were
also interested in comparing CBT with an equivalent, manualised
treatment, in addition to potential differences in the mechanisms
of action of CBT and family intervention. We therefore random-
ised between treatment as usual, treatment as usual plus CBT,
and treatment as usual plus family intervention. We avoided
methodological limitations of earlier trials, specifically lack of
assessor masking, sample attrition and inadequate statistical
methods for handling missing data.15
Methods
Study design
This multicentre randomised controlled trial (ISRCTN83557988)
comprised two pathways with separate randomisation. The first
pathway (‘no carer pathway’) included those without carers
randomly allocated to two groups: both groups received good
standard care (treatment as usual), with the addition of CBT to
one of the groups. In the second pathway (‘carer pathway’), those
with carers were allocated to three groups (CBT plus treatment as
usual; family intervention plus treatment as usual; or treatment as
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Background
Family intervention reduces relapse rates in psychosis.
Cognitive–behavioural therapy (CBT) improves positive
symptoms but effects on relapse rates are not established.
Aims
To test the effectiveness of CBT and family intervention in
reducing relapse, and in improving symptoms and
functioning in patients who had recently relapsed with non-
affective psychosis.
Method
A multicentre randomised controlled trial (ISRCTN83557988)
with two pathways: those without carers were allocated to
treatment as usual or CBT plus treatment as usual, those
with carers to treatment as usual, CBT plus treatment as
usual or family intervention plus treatment as usual. The CBT
and family intervention were focused on relapse prevention
for 20 sessions over 9 months.
Results
A total of 301 patients and 83 carers participated. Primary
outcome data were available on 96% of the total sample.
The CBT and family intervention had no effects on rates of
remission and relapse or on days in hospital at 12 or 24
months. For secondary outcomes, CBT showed a beneficial
effect on depression at 24 months and there were no effects
for family intervention. In people with carers, CBT
significantly improved delusional distress and social
functioning. Therapy did not change key psychological
processes.
Conclusions
Generic CBT for psychosis is not indicated for routine relapse
prevention in people recovering from a recent relapse of
psychosis and should currently be reserved for those with
distressing medication-unresponsive positive symptoms. Any
CBT targeted at this acute population requires development.
The lack of effect of family intervention on relapse may be
attributable to the low overall relapse rate in those with
carers.
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usual alone). Randomisation was also stratified within each of the
five participating centres and within in-patient or out-patient
status at the time of relapse. Randomisation schedules were
independently generated by a trial randomisation service in a
separate location from all trial centres (accessed by telephone),
using randomised permuted blocks with a block size randomly
varying between two and ten for the no carer pathway and three
and nine for the carer pathway. Each patient’s first assessment
was completed after screening and informed consent for inclusion,
but before randomisation.
Participants
Participants were recruited by approaching consecutive patients
who had recently relapsed, whether or not they had been
admitted. After this index relapse, patients were screened and
invited to take part as soon as they were thought able to give
informed consent. The inclusion criteria were:
(a) a current clinical diagnosis of non-affective psychosis (ICD–10
category F2 and DSM–IV);
(b) age 18–65 years;
(c) a second or subsequent psychotic episode starting not more
than 3 months before they agreed to enter the trial;
(d) a rating of at least 4 (moderate severity) for at least one
positive symptom on the Positive and Negative Syndrome
Scale (PANSS).17
Criteria for exclusion from the trial were:
(a) a primary diagnosis of alcohol or substance dependency,
organic syndrome or intellectual disability;
(b) a command of spoken English inadequate for engaging in
psychological therapy;
(c) unstable residential arrangements such that the likelihood of
being available for the duration of the trial was low.
Participants provided informed consent under protocols
approved by the South Thames Multi-Centre Research Ethics
Committee and the local research ethics committees of each of
the participating centres.
Allocation to no carer and carer pathway
If patients had no carer with whom they had close contact, they
were invited to participate in the no carer pathway. If patients
identified a carer, a relative or friend with whom they lived or were
in close contact for at least 10 h each week, the patient was asked
to give informed consent for the carer pathway study. Once the
patient had consented, the carer was also approached for
consent. At the trial recruitment mid-point, it had become
apparent that otherwise eligible patients with carers had been
excluded from the study because they or their carers had refused
to allow carer participation. A protocol change was made with
the approval of the ethical committees mentioned earlier and
the Trial Steering Committee: from that point, in cases where
patients or carers refused carer participation, participants with
carers were offered the opportunity to enter in the trial in the
no carer pathway, with random allocation to CBT plus treatment
as usual or treatment as usual alone. A total of 32 such parti-
cipants were subsequently included. All analyses incorporated
separate testing for any effects of this sub-group on outcomes.
Recruitment
Recruitment to the trial occurred between January 2002 and July
2004. A total of 683 patients meeting inclusion criteria were
identified; 301 patients provided informed consent (44%), of
whom 218 entered the no carer pathway, and 83 entered the carer
pathway (Fig. 1). In addition, 382 patients withheld consent to the
trial. Those who consented did not differ in age from those who
did not, but they were more likely to be male (w2=8.23, d.f.=1,
P=0.004). In the no carer pathway, 106 participants were allocated
to CBT plus treatment as usual and 112 to treatment as usual,
while in the carer pathway, 28 participants were allocated to family
intervention plus treatment as usual, 27 to CBT plus treatment as
usual, and 28 to treatment as usual. For each patient in the carer
pathway, there was one corresponding main carer from whom
data were collected: there were, thus, 83 carers.
Participants were assessed at baseline before randomisation,
and at 3, 6, 12 and 24 months. The intervention treatments were
all completed by 12 months, but treatment as usual continued
throughout.
Settings
The trial was set in five local mental health services in London and
East Anglia: two in inner London, one in suburban London, one
in Norwich and one at a centre in rural Norfolk. These settings
differ in levels of social deprivation, in the proportion of patients
with carers and in their ethnic composition.
Treatments
Cognitive–behavioural therapy and family intervention were both
delivered for 9 months with a planned minimum of 12 and a
maximum of 20 sessions.
Cognitive–behavioural therapy
The therapy was an adaptation of our generic CBT for psychosis
manual18 specifically aimed to target key aspects of relapse pre-
vention highlighted by our cognitive model.19 The first stage
focused on engagement and assessment, with the key task of fos-
tering and maintaining a good psychotherapeutic relationship
with people who would initially be in an acute psychotic state.
A central focus of the work was developing a shared formulation
of relapse. This was done by exploring people’s understanding of
triggers and risks of relapse and, where appropriate, by developing
a new model of disorder emphasising alternatives to delusional
thinking.20 Therapists then attempted to target the key problems
associated with vulnerability to relapse, as identified by the
personal formulation. Targets would often include persistent
negative beliefs about self and others, characteristic reasoning
styles such as jumping to conclusions and distressing emotional
reactions to events and anomalous experiences. The last stage
involved developing a set of self-regulatory strategies to manage
relapse. This would include a pragmatic relapse management plan
and the identification of particular behavioural strategies to
manage risk situations and early signs as they emerged.
Family intervention
Family intervention followed the manual of Kuipers et al21 with an
emphasis on improving communication, offering discussion of
up-to-date information about psychosis, problem-solving,
reducing criticism and conflict, improving activity, and the
emotional processing of grief, loss and anger. All family members
who were willing and available were invited to participate in
sessions. Sessions focused on one problem at a time and were
aimed at an individual formulation of each family’s problems as
they defined them. There was a particular focus on relapse preven-
tion, including how family members might understand warning
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signs and agree on appropriate intervention, including medi-
cation. Sessions were collaborative, involved two therapists and
usually took place at home. Therapy sessions were tape-recorded
(with permission) and therapists were monitored for adherence
and competence.
Trial therapists, training and monitoring of adherence
and competence
Cognitive–behavioural therapy
Five lead trial therapists, all doctorate level or equivalent clinical
psychologists employed full time on the trial, provided CBT for
96 individuals (72% of the total). A further 37 participants
receiving CBT were seen by therapists employed by the local
mental health services. These therapists were a mix of doctoral
clinical psychologists and nurses who had received specialist
training in CBT. All therapists were required to demonstrate
competence in CBT before recruitment. This included submitting
tapes of therapy that passed standards of competence in CBT. Lead
therapists were also required to demonstrate key techniques in
role-play as part of their recruitment. This was followed by a
period of intensive training in workshops with both the expert
CBT therapists on the trial (D.F., P.G. and E.K.) and external
experts. These workshops continued throughout the trial.
Lead therapists from each centre met monthly with the expert
CBT therapists to discuss each patient and for supervision. A total
of 106 patients (80%) consented to sessions being tape-recorded.
Supervision consisted of regular discussions and reviews about
each individual, using the taped sessions. Therapists were moni-
tored for key CBT competencies with regard to structure, therapy
skills and collaboration, and the use of CBT techniques, as
suggested in the Cognitive Therapy Scale (CTS).22 They were,
however, allowed flexibility with regard to agenda-setting and
homework in order to take account of client sensitivities. Formal
monitoring of tapes was carried out using the Cognitive Therapy
for Psychosis Adherence Scale (CTPAS)23 and the CTS22 through-
out the trial, with lead therapists monitoring samples of tapes
from other centres. A total of 185 tapes from 66 patients (62%
of the total treated) were sent to another centre for formal
monitoring. These ratings indicated that in 90% of the sample
the therapy delivered in taped interviews was adherent and com-
petent CBT (i.e. above the standard CTS cut-off for competent
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inclusion criteria (n=683)
Assessed and randomised (n=301)
Not randomised – did not consent (n=382)
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n=218
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n=83
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Full dose
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Withdrawn (n=14)
Secondary outcomes
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6 months (n=90)
End of treatment at:
12 months (n=90)
Missed (n=6)
Withdrawn (n=10)
Secondary outcomes
3 months (n=26)
6 months (n=24)
End of treatment at:
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Withdrawn (n=4)
Secondary outcomes
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End of treatment at:
12 months (n=23)
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Primary outcomes
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Secondary outcomes
(n=87)
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Primary outcomes
(n=109)
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Primary outcomes
(n=28)
Secondary outcomes
(n=25)
24 Months
Primary outcomes
(n=27)
Secondary outcomes
(n=22)
Fig. 1 Diagram of the flow of participants through the trial.
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CBT and adherent on the CTPAS). In eight patients (10%), the
therapy was regarded as supportive work rather than CBT. To
check on the anchoring of these internal ratings, a randomly
selected sub-sample of 18 tapes was sent to an external expert
rater during the trial, and a further 18 tapes were sent to three
other external experts in CBT in psychosis after the trial. Of these
tapes, 34 had been rated as adherent and competent CBT by the
internal raters, and all were confirmed as such by the external
raters. The internal rating of one therapy session as supportive
therapy was confirmed, and one session was likewise agreed to
be CBT of minimal quality.
Family intervention
Family intervention involved a lead and a co-therapist working
together. The five lead trial therapists for CBT also acted as lead
family intervention therapists to all 28 participants.
As part of the recruitment process, all lead therapists were
required to show in-depth knowledge of evidenced-based family
intervention in psychosis, and to demonstrate key techniques in
role-play. They also attended intensive training from an expert
family intervention therapist (E.K.). All co-therapists attended
family intervention training workshops or received individual
training from a trial lead therapist. As with the CBT, the local
therapists were a mix of doctoral level clinical psychologists and
nurses who had received training in family intervention.
The trial lead therapists were provided with specialist expert
monthly supervision throughout the trial and attended advanced
skills workshops by E.K. and another expert. The lead therapists
also met fortnightly for peer supervision and case presentations.
A total of 82% (n=23) of 28 participants provided consent to tape
record the therapy sessions. Supervision involved listening to
complete tape-recorded sessions or long excerpts.
The formalised monitoring of recorded therapy sessions,
internally and externally, was undertaken using an additional
section on Family Intervention incorporated into the CTPAS23
and parts of the Family Intervention Competence Rating Scale
developed in 1992 (D. Lam, personal communication, 2007).
For internal monitoring, E.K. and one of the lead therapists
checked the therapy quality of a sample of 13 tapes. These ratings
indicated that all therapy provided was both adherent and compe-
tent. As a further external check of therapy fidelity, a random
selection of 11 therapy tapes (39% of 28 patients) were sent to
an external expert rater. She rated 100% of the randomised tapes
as adherent, and confirmed that family intervention did not over-
lap in techniques with CBT intervention.
Control condition
Treatment as usual consisted of good standard care delivered
according to national and local service protocols and guidelines,
including the prescription of antipsychotic medication. The
frequency and nature of service contacts was monitored, as was
the prescription of medication. Treatment as usual did not
preclude the provision of psychological interventions, although
in practice this was relatively rare, as reported below.
Reliability of research assessments
Baseline assessments were conducted by a trial research worker,
after patient consent had been obtained. The aim was to complete
the assessment within a 3-week period. Interviews were tape-
recorded for reliability and quality control purposes. Research
workers met regularly throughout the trial to maintain reliability
of procedures and ratings. Reliability of interview ratings was
assessed using the PANSS positive symptom score. At least one
other assessor (selected from a panel of 15 raters – excluding
the rater responsible for the initial assessment) re-rated 55 assess-
ments. The number of re-ratings varied between 1 and 6, and the
total number of ratings made by the 15 raters varied between
2 and 27.
A linear one-way random effects model (with participant
identification as the explanatory factor) was fitted by restricted
maximum likelihood using Stata’s xtreg procedure (version 8 for
Windows) and yielded an intraclass correlation of 0.88 (95% CI
0.82–0.92). This indicates very acceptable interrater reliability.
Masking procedures
Trial research assessors were independent of treatment delivery
and every effort was made to ensure they were kept masked to
allocation. The primary outcome variable, relapse, was assessed
by masked panel evaluation following the procedure described
by Craig et al1 and Bebbington et al.24 In order to test the success
of masking with regard to the primary outcome, panel assessors
guessed whether each participant had been allocated to receive
CBT, family intervention or treatment as usual. The raters had a
bias towards guessing that patients were in the treatment as usual
condition. Thus, in the no carer pathway, averaging across four
raters, CBTwas guessed correctly in 22% of patients and treatment
as usual was guessed correctly in 73% of patients. This indicates
that information on the receipt of psychological treatment was
successfully removed from the data used to rate relapse.
Secondary outcomes were rated by research assessors in inter-
views and considerable effort was made to achieve masked ratings.
The following strategies were used:
(a) research workers were not involved in the randomisation
process;
(b) therapists were encouraged to consider room use and diary
arrangements in the light of potential breaks of masking;
(c) patients were reminded by the assessors not to talk about
treatment allocation;
(d) after the initial assessment, the assessor did not look at the
patient’s clinical notes until the last of their ratings had been
collected;
(e) in the few cases where masking was broken, another rater
assessed the patient for the final assessment;
(f) on the occasions when masking was broken again by patients
with the second rater, this was noted in the data file;
(g) in all cases, after patients had completed the final assessment,
the assessor was instructed to make an allocation guess.
Of the 24-month assessments, 88% were completed masked
(i.e. the allocation of the patient had not been revealed to the
assessor). Of these masked rater assessments, the assessors guessed
CBT allocation correctly for 54%, treatment as usual allocation
correctly for 63% and family intervention correctly for 42%,
similar to what would be expected by chance.
Diagnostic verification
Induction was based on a clinical diagnosis of non-affective psy-
chosis. In order to consider whether this diagnosis was sustainable
at the end of the trial, we used detailed descriptions of clinical
progress to amplify the information about symptoms obtained
at baseline by using the Schedules for Clinical Assessment in
Neuropsychiatry (SCAN).25 This resulted in some diagnostic shift.
Thus, at follow-up, 91% of participants continued to fulfil criteria
for non-affective psychosis (ICD–10 F2), whereas 9% were
diagnosed as having affective psychosis.
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Demographic and clinical data
Data on age, gender, ethnicity, admissions, contact with services,
and medication were taken from clinical notes. Adverse events
were also recorded.
Primary outcome measures
Remission and relapse ratings were made using a published
method employed in a previous randomised controlled trial.1,24
Consensus ratings are made by paired members of the research
team using manualised a priori operationalised definitions, a
method with moderate to good reliability (kappa values of 0.56
and 0.71 for the identification of remission and relapse respec-
tively between paired raters) and good validity (independent
PANSS ratings were strongly related to the remission/relapse
ratings of participants).24 Ratings are based on changes in positive
psychotic symptoms. Evidence is required of improvement in (for
partial remission) or absence of (for full remission) positive
psychotic symptoms continuing for at least 4 weeks. Relapse
ratings are based on evidence of the re-emergence of, or significant
deterioration in, positive psychotic symptoms of at least moderate
degree persisting for at least 2 weeks.24
In the present study, the ratings were applied to detailed
extracts of the clinical case notes. These consisted of monthly
reports over 24 months on mental state and service interventions,
from which all information that might provide clues as to whether
the patient was being seen for CBT or family intervention had
been removed. Group allocation remained concealed until all
the ratings were complete.
Data on all hospital admissions were collected through the
hospital administration systems.
Secondary outcome measures
Psychotic symptom measures
The PANSS is a 30-item, 7-point (1–7) rating instrument
developed for the assessment of phenomena associated with
schizophrenia.17 Symptoms over the past week are rated. Four
scores are obtained: total (30 items), positive scale (7 items),
negative scale (7 items) and general psychopathology (16 items).
The Psychotic Symptom Rating Scales (PSYRATS) is a 17-
item, 5-point scale (0–4) multidimensional measure of delusions
and hallucinations.26 Symptoms are rated over the previous week.
Two items each from the delusions scale (conviction and distress)
and from the hallucinations scale (frequency and distress) were
recorded.
Measures of affect
The Beck Depression Inventory Second Edition (BDI–II) is a self-
report 21-item, 4-point scale (0–3) for the assessment of depres-
sion.27 Depression is assessed over the previous fortnight. A total
score is usually used.
The Beck Anxiety Inventory (BAI) is a self-report 21-item,
4-point scale (0–3) for the assessment of anxiety.28 Anxiety is
assessed over the previous week. A total score is usually used.
Social functioning
The time-budget measure is an interview measure of social
functioning, designed to be sensitive to changes in activity levels.29
Time spent by the interviewees participating in activities four
times a day (morning, lunch, afternoon, evening) over the pre-
vious 7 days are assessed and rated on a 0–4 scale. If necessary,
a more typical week in the recent past is used for the assessment
period. Increasing scores reflect increasingly demanding activities
(in terms of both time occupied and complexity of task). Partic-
ular care is taken during the interview to elicit social activities.
A total score of activity over the week is derived; additionally,
the combined total score of ratings of 0 and 1 provides a measure
of time spent in no or minimal activity. The scale has good
interrater reliability and validity.
Social and occupational functioning is rated on a scale of
0–100 by the assessor using the Social and Occupational Functioning
Assessment Scale (SOFAS).30
Service receipt
Service use is measured for a retrospective 6-month period using
the Client Service Receipt Inventory (CSRI).31 The CSRI covers
services provided by the National Health Service, other health
and social care agencies, the criminal justice system and informal
carers. Data are collected from clinical notes, patients, carers and
case managers.
Measures of therapy process
The following measures of therapy process were used.
(a) The Scale to Assess Unawareness of Mental Disorder.32 This
scale is a multidimensional measure of current and past
insight.
(b) The Illness Perception Questionnaire, which has been adapted
for use in psychosis (as reported by Watson et al33), is a self-
rated measure of the subjective perception of illnesses, in five
dimensions: subjective symptoms, causes, cure/control,
consequences, timeline.34 It has good reliability and validity.
(c) The Brief Core Schema Scales is a rapid self-rated measure of
negative and positive evaluations of self and others,35 with
good reliability and validity.
(d) Reasoning – three key aspects of reasoning in delusions were
assessed: jumping to conclusions;36 belief flexibility (Maudsley
Assessment of Delusions Schedule);37 and alternative explana-
tions for delusional experiences (Explanations of Experience
Interview).20
Intellectual functioning
The Quick Test provides an estimate of current intellectual func-
tioning.38
Carer measures
The Camberwell Family Interview was administered by trained
research workers and was subsequently used to assess levels of
expressed emotion (EE): the number of critical comments,
hostility, emotional overinvolvement, number of positive
comments, and warmth.39 High EE is rated if a respondent scores
3 or above on emotional overinvolvement, 1 or above on hostility,
or makes 6 or more critical comments. All raters were trained to
criterion by Dr Christine Vaughn.
The self-report questionnaire Experience of Care-giving
Inventory is designed to assess the experience of caring for a
relative with a serious mental illness.40 The 66-item questionnaire
has 10 sub-scales: difficult behaviour, negative symptoms, stigma,
problems with services, effects on the family, the need to provide
back-up, dependency, loss, rewarding personal experiences, and
good aspects of the relationship with the patient.
Another self-report screening questionnaire, the General
Health Questionnaire–28, is aimed at detecting those with a
diagnosable psychiatric disorder.41 There are four sub-scales:
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somatic symptoms, anxiety and insomnia, social dysfunction and
severe depression.
Hypotheses concerning outcome
The primary outcome hypothesis for the no carer pathway was
that CBT, when added to good standard care (treatment as usual),
would reduce the rates of relapse and total days in hospital at
2-year follow-up, compared with treatment as usual alone. For the
carer pathway, it was hypothesised that both CBTand family inter-
vention, when added to good standard care (treatment as usual),
would reduce the rates of relapse and total days in hospital at
2-year follow-up, compared with treatment as usual alone.
With regard to secondary outcomes, it was hypothesised that
over both trial pathways CBT and family intervention would
reduce relapse and psychotic and emotional symptoms at 12
months (end of treatment); that CBT but not family intervention
would reduce psychotic and emotional symptoms at 24 months
compared with treatment as usual; and that family intervention
but not CBT would improve social functioning at 24 months
compared with treatment as usual.
The treatment mediator hypotheses were that CBT but not
treatment as usual would lead to improvements in schemas,
insight and illness perceptions, and reasoning; and that family
intervention but not treatment as usual would lead to improve-
ments in EE, burden and mental health in carers.
Statistical analysis
Power
The following sample size calculations are from the original
protocol. They were based on the primary outcome measure of
relapse rate. Those with treatment as usual were predicted to have
a relapse rate of 50% at 2 years. Those who had CBTwere predicted
to have a relapse rate of 30%. A total of 140 participants per cell of
the no carer pathway would give 90% power to detect this differ-
ence using a simple w2 test at 5% significance. We predicted that
the main effect of family intervention was slightly better – a 25%
relapse rate at 2 years. We would have around 90% power in the
carer pathway with 75 participants per cell. All power calculations
were carried out using nQuery Advisor.42 Although the protocol
specified that the effect of CBT should be estimated by a joint
analysis of the data from both pathways, the possibility of gaining
extra power in this way was not explicitly considered at that stage.
Following the mid-trial protocol changes to the pathway
recruitment criteria (allowing those with non-consent for carer
involvement to be randomised into the no carer pathway), sample
size and power considerations were revisited. The revised recruit-
ment targets required randomising at least 100 participants to
each of the two treatment arms in the no carer pathway and about
33 participants to each of the three arms of the carer pathway.
Thus there would be about 133 participants receiving CBT and
a similar number receiving treatment as usual. Provided that the
analysis of the data from the two pathways was undertaken jointly,
the power to detect a clinically significant difference in relapse
rates (30% v. 50%, as before) would be for all practical purposes
the same as that originally planned for the no carer pathway. It
was explicitly acknowledged, however, that there would be
inadequate power for the evaluation of family intervention, but
a decision was taken to continue with recruitment to this pathway
because it would provide valuable information on symptom
severity and mediating variables.
Data analysis
All analyses reported here were based on the intention-to-treat
principle, with due consideration being given to potential biases
arising from loss to follow-up. The main analyses were aimed at
estimating treatment effects using data from both pathways
simultaneously. This resulted in estimates of the effects of CBT
(relative to treatment as usual) that were common to both path-
ways; estimates of the effect of family intervention (relative to
treatment as usual) were, of course, applicable only to the carer
pathway. Multiple regression models (or equivalent logistic
models, in the case of binary data) were fitted to estimate separate
treatment effects for outcomes at 12 and 24 months, controlling
for pathway (two levels), treatment centre (five levels), in-patient
status (two levels) and, where relevant and available, the
corresponding baseline assessment for the outcome under investi-
gation. Analyses of lengths of hospital admissions used
untransformed data, but employed bootstrapping to generate
valid 95% confidence intervals for the treatment effects. All
analyses were carried out using Stata version 9.43 We allowed for
the presence of missing outcome data under the assumption that
the data are missing completely at random conditional on the cov-
ariates included in the regression models (i.e. missing at random,
using the terminology of Little & Rubin).44 The sensitivity of the
results to departures from this assumption was checked for the
main secondary outcomes (symptom severity measures as pro-
vided by the PANSS) through the use of inverse probability
weights.45,46 Here, the probability of having a non-missing PANSS
score was modelled and predicted separately using logistic
regression for those not offered an intervention treatment and
those offered either CBT or family intervention. This was carried
out separately for 12- and 24-month outcomes. The variables used
in the logistic regression models were relevant baseline PANSS
score, pathway, treatment centre, in-patient status, gender and
clinical outcome (number of months in partial or full remission
over the first 12 months and also over the second 12 months).
An inverse probability weight for each individual participant
providing the relevant outcome measurement was then calculated
as the reciprocal of the modelled probability of providing a
non-missing outcome.
In a separate series of exploratory analyses (i.e. that were not
part of the original analysis plan), the treatment effects on selected
outcome variables were again estimated for participants in both
pathways, using the same models as above, but after first excluding
those without a carer (thus estimating the treatment effects for
those with carers, irrespective of whether they actually entered
the carer pathway of the trial).
Results
Demographic and clinical characteristics
of participants
A total of 301 patients and 83 carers participated in the study. The
socio-demographic and clinical characteristics of the patients (on-
line Tables DS1 and DS2) and of the carers (online Table DS3) did
not differ between groups.
Therapy provision
One hundred and thirty-three people were allocated to CBT. They
received a mean of 14.3 sessions (s.d.=7.8), each session lasting on
average 1 hour. Those in the no carer pathway (n=106) received a
mean of 14.4 sessions (s.d.=7.8); those in the carer pathway
(n=27), a mean of 13.9 sessions (s.d.=8.0); the group with carers
allocated to the no carer pathway (n=18) received a mean of 15.1
sessions (s.d.=8.8). Twenty-eight families were allocated to the
family intervention. They received a mean of 13.9 sessions
(s.d=7.5) or 14.1 h of therapy (s.d.=7.9). Figure 1 shows therapy
sessions in each pathway, including the numbers of participants
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receiving a partial (6–11 sessions) or full (12 or more sessions)
‘dose’ of therapy.
Provision of non-intervention therapy
and medication
We used the CSRI to examine non-intervention counselling or
psychological therapy delivered to the treatment and control
(treatment as usual) groups in the 6 months preceding baseline,
and in the two 12-month periods following induction. The pro-
vision of psychological therapy in addition to the trial inter-
ventions was rare, was more often than not non-significant in
group comparisons, and favoured treatment as usual where it
occurred. At baseline there were no differences in either pathway
between treatment and control groups in the mean number of
therapist contacts for other interventions. At 12 months following
induction, there were no differences in the no carer pathway, but
there were small but statistically significant differences in the carer
pathway: those allocated to treatment as usual were more likely
than those allocated to CBT or to family intervention to have an
additional non-intervention therapy (Fishers exact w2=5.6,
d.f.=1, P=0.041). Three people in treatment as usual received a
non-intervention therapy, compared with none in the family in-
tervention or CBT groups. Between 12 and 24 months following
induction, there was no longer a difference between the groups
in the carer pathway (with one person in treatment as usual,
one in CBT and none in family intervention receiving non-inter-
vention therapy); nor was there a significant difference between
CBT and treatment as usual groups in the no carer pathway (eight
participants in treatment as usual and two in CBT had been re-
ceiving a non-intervention therapy).
Antipsychotic medication data were extracted from medical
records and dosages were converted into chlorpromazine equiva-
lents grouped into low (0–200mg), medium (200–400mg) and
high (5400mg). Changes in all medication from baseline to 12
months and from 12 months to 24 months were recorded as no
change, increasing or decreasing doses. Additionally, clozapine
was recorded as commenced, stopped or unchanged. There were
no differences between the groups in baseline medication or in
changes in medication over the course of the trial.
Primary outcomes
Primary outcome data were available on 96% of the total sample.
There were no differences between the groups, in either pathway,
in the primary outcomes of patterns of remission and relapse, and
total days in hospital at 12 months or at 24 months (Tables 1 and
2). It will be seen from Table 1 that the proportion of participants
who made a full remission from the index episode was
disappointingly low (less than 50%). This makes the planned
intention-to-treat analysis of subsequent relapse problematic.
Most participants did, however, make a partial remission. Survival
curves (not shown) for full or partial remission failed to reveal any
interesting treatment effects (median remission times from the
initial episode being about 3 months in the no carer pathway,
and 2 months in the carer pathway). Whether we examine full
remission and the possibility of relapse from full remission, or
the less stringent criterion of full or partial remission and sub-
sequent relapse, it is clear from Table 1 that there are no signs
of any treatment effects in either pathway. In order to carry out
a formal analysis of treatment effects, we used months in partial
or full remission as our indicator of the primary outcome.
Summary statistics and estimated treatment effects are given in
Table 2. Again, there is no evidence of any treatment effects.
The results for the number of hospital admissions (in addition
to any admission at the time of randomisation) and days spent
in hospital (within the first 12 months and between 12 and 24
months) again fail to reveal any significant treatment effects.
Secondary outcomes
Secondary outcome data were available for 82% of the total
sample at 12 months and for 80% at 24 months.
Psychotic and emotional symptoms
The mean scores at baseline, 12 and 24 months on the PANSS
total, positive, negative and general symptoms for each group in
the no carer and carer pathway are presented in online Table
DS4. It also presents the same data for the PSYRATS, hallucination
frequency (A1) and distress (A8), and delusional conviction (B1)
and distress (B4). All these scores declined over the course of the
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Table 1 Primary outcomes: patterns of remission and relapse for patients with and without carers
No carer pathway Carer pathway
No, n Yes, n (%) Total, n No, n Yes, n (%) Total, n
Full remission from initial episode
TAU 61 48 (44.0) 109 14 14 (50.0) 28
CBT 57 47 (45.2) 104 14 13 (48.2) 27
Family intervention 18 9 (33.3) 27
Relapse following full remission from initial episode
TAU 31 17 (35.4) 48 11 3 (21.4) 14
CBT 25 22 (46.8) 47 10 3 (27.3) 13
Family intervention 7 2 (22.2) 9
Partial or full remission from initial episode
TAU 17 92 (84.4) 109 1 27 (96.4) 28
CBT 7 97 (92.3) 104 2 25 (92.6) 27
Family intervention 3 24 (88.9) 27
Relapse in those with partial or full remission from initial episode
TAU 58 34 (37.0) 92 20 7 (25.9) 27
CBT 44 53 (54.6) 97 18 7 (28.0) 25
Family intervention 19 5 (20.8) 24
Participants with a ‘good’ outcome – partial or full remission, without further relapse
TAU 51 58 (53.2) 109 8 20 (71.4) 28
CBT 60 44 (42.3) 104 9 18 (66.7) 27
Family intervention 8 19 (70.4) 27
CBT, cognitive–behaviour therapy; TAU, treatment as usual.
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trial in all groups. Scores on the BDI and BAI are given in online
Table DS5. In Table 3, we show the treatment effect estimates for
the difference in mean scores between CBT and treatment as usual
and family intervention and treatment as usual on the PANSS,
PSYRATS, BDI and BAI at 12 and 24 months. Almost none of the
results were significant. The only exception was a significant differ-
ence between treatment as usual and those who received CBT in
improvements in depression at 24 months, favouring CBT. A
weighted analysis of the 24-month PANSS outcomes (to allow for
missing data) produced results very similar to those given in Table 3.
In a separate, exploratory, series of analyses, we examined the
data for people with carers, irrespective of whether they had been
recruited to the no carer or carer pathways. Selected change scores
are summarised in online Table DS6. It will be seen that similar
change scores were shown for CBT for people with carers, whether
they were in the no carer or the carer pathway, and for family
intervention in the carer pathway, apparently favouring both
treatments over treatment as usual. These change scores were
generally greater than those for CBT in the no carer pathway.
The estimated treatment effects for people with carers of CBT
and of family intervention, both compared with treatment as
usual, are shown in Table 4. There was a statistically significant
reduction in delusional distress at 12 months for those with carers
who received CBT; all other results for psychotic and emotional
symptoms were non-significant, although a number of other
variables indicate a consistent treatment effect that might be
common to both CBT and family intervention. Both CBT and
family intervention treatments were then combined in a further
exploratory analysis: the estimated treatment effects on PANSS
scores of receiving a psychological treatment, whether CBT or
family intervention, for people with carers are shown in Table 5.
At 12 months, treatment resulted in significantly better PANSS
total scores and PANSS negative symptom scores. At 24 months
there were significant benefits on PANSS general symptom scores.
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Table 2 Primary outcomes: remission and total number of days in hospital for patients with and without carers
No carer pathway Carer pathway
TAU CBT TAU CBT FI
Outcome n Mean s.d. n Mean s.d. n Mean s.d. n Mean s.d. n Mean s.d.
Months in partial or full remission
0–12 month period 109 7.29 4.60 104 7.33 4.46 28 8.79 3.74 27 7.85 4.65 27 7.48 4.67
12–24 month period 106 8.46 4.73 103 8.60 4.22 26 10.00 3.61 27 9.96 3.73 27 9.93 4.08
Days in hospital and number of admissions (excluding any admission at time of randomisation)
0–12 month period 105 62.51 104.76 102 61.86 87.72 26 35.62 92.63 27 21.07 51.55 27 29.67 46.18
12–24 month period 105 42.94 81.10 103 46.00 80.05 26 13.88 39.79 27 14.07 44.06 27 30.33 73.39
Number admissions 106 0.79 1.14 104 1.17 1.62 26 0.31 0.55 27 0.63 1.18 27 0.96 2.08
Treatment effect estimates (95% CI)
0–12 months 12–24 months
CBT FI CBT FI
Months in remission 70.15 (71.22 to 0.91) 70.89 (73.01 to 1.23) 0.09 (70.95 to 1.14) 70.06 (72.13 to 2.01)
Days in hospitala 74.23 (724.40 to 16.26) 3.55 (723.75 to 33.37) 2.27 (715.94 to 20.10) 19.13 (711.10 to 51.68)
CBT, cognitive–behavioural therapy; FI, family intervention; TAU, treatment as usual.
a. Confidence interval from 1000 bootstrap samples, using the non-parametric (percentile) method.
Table 3 Treatment effect estimates: difference in means (95% CI) between treatment condition (cognitive–behavioural therapy or
family intervention) and treatment as usual
12 months 24 months
CBT FI CBT FI
PANSS
Total 71.53 (75.28 to 2.22) 74.26 (711.68 to 3.17) 70.03 (73.72 to 3.66) 73.03 (710.59 to 4.53)
Positive 70.74 (72.20 to 0.73) 71.22 (74.09 to 1.65) 0.78 (70.83 to 2.38) 2.06 (71.15 to 5.27)
Negative 70.55 (71.80 to 0.71) 71.51 (74.02 to 1.00) 70.01 (71.25 to 1.23) 70.65 (73.17 to 1.87)
General 70.30 (72.19 to 1.60) 71.43 (75.16 to 2.31) 70.77 (72.59 to 1.04) 72.43 (76.14 to 1.28)
PSYRATS
A1 70.10 (70.65 to 0.46) 70.22 (71.18 to 0.75) 70.07 (70.60 to 0.45) 70.35 (71.28 to 0.58)
A8 70.10 (70.72 to 0.51) 70.37 (71.47 to 0.73) 0.09 (70.52 to 0.70) 1.03 (70.06 to 2.13)
B1 70.02 (70.41 to 0.38) 0.35 (70.41 to 1.12) 0.11 (70.27 to 0.50) 0.54 (70.23 to 1.32)
B4 70.13 (70.64 to 0.39) 0.11 (70.84 to 1.06) 70.03 (70.60 to 0.54) 70.25 (71.35 to 0.85)
BAI 1.93 (71.24 to 5.10) 71.27 (77.48 to 4.93) 0.59 (72.92 to 4.11) 73.13 (710.45 to 4.19)
BDI 70.28 (73.38 to 2.81) 0.98 (75.01 to 6.97) 73.07 (76.04 to 70.11)* 70.36 (76.35 to 5.63)
Time budget
Total 5.25 (70.89 to 11.38) 72.38 (714.05 to 9.29) 2.55 (72.81 to 7.91) 5.97 (74.61 to 16.55)
Zero/one 71.86 (74.09 to 0.36) 0.98 (73.28 to 5.23) 71.87 (74.02 to 0.29) 73.23 (77.51 to 1.06)
SOFAS 2.77 (71.02 to 6.55) 1.90 (75.52 to 9.32) 2.42 (71.42 to 6.26) 2.13 (75.78 to 10.04)
EuroQol 74.68 (710.93 to 1.57) 75.91 (718.80 to 6.99)
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CBT, cognitive–behavioural therapy; EuroQol, Quality of Life measure; FI, family intervention; PANSS, Positive and
Negative Syndrome Scale; PSYRATS, Psychotic Symptom Rating Scale (A1, hallucination frequency; A8, hallucination distress; B1, delusional conviction; B4, delusional distress);
SOFAS, Social and Occupational Functioning Assessment Scale; TAU, treatment as usual; zero/one, mean number of time periods rated 0 or 1 on time budget.
*P50.05.
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Social functioning
The mean scores on our measures of social functioning and
quality of life (time budget total, time doing nothing, SoFAS
and EuroQol47) are presented in online Table DS5. Table 3 presents
the estimated treatment effects on these measures: there were no sig-
nificant effects. As for the symptoms, we also separately examined
the effects of CBT in the group with carers allocated to the no
carer pathway and the effects of CBT and of family intervention
in the carer pathway (Table 4). This showed a significant improve-
ment in social functioning (SoFAS scores) at 12 months, in those
with carers who received CBT. There is also a significant effect on
social functioning (SoFAS scores) of receiving a psychological
treatment (whether CBT or family intervention (Table 5).
Treatment mediators
There were no significant changes in the predicted direction of the
treatment mediators, with the exception of greater reductions in
levels of criticism (EE) in those who were in receipt of family
intervention, as hypothesised.
Adverse events
There were three patient deaths over the course of the trial, all in
the treatment as usual condition. The causes were suicide,
pulmonary embolism and kidney failure. Two carers also died,
one in the treatment as usual and one in the family intervention
condition, recorded respectively as natural causes and lung cancer.
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Table 4 Treatment effect estimates for patients with carers: difference in means (95% CI) between treatment condition
(cognitive–behavioural therapy or family intervention) and treatment as usual
12 months 24 months
CBT FI CBT FI
PANSS
Total 75.90 (712.34 to 0.54) 76.44 (714.12 to 1.24) 75.32 (712.20 to 1.56) 76.25 (714.77 to 2.28)
Positive 71.13 (73.57 to 1.30) 71.48 (74.31, 1.35) 71.07 (73.80 to 1.67) 1.17 (72.13 to 4.46)
Negative 72.08 (74.39 to 0.23) 72.42 (75.18, 0.35) 70.87 (73.37 to 1.62) 71.32 (74.42 to 1.78)
General 72.82 (76.17 to 0.54) 72.66 (76.60 to 1.28) 73.01 (76.29 to 0.27) 73.98 (78.02 to 0.06)
PSYRATS
A1 71.02 (72.13 to 0.08) 70.69 (71.82 to 0.44) 70.07 (71.12 to 0.97) 70.45 (71.51 to 0.62)
A8 70.68 (71.99 to 0.63) 70.50 (71.89 to 0.90) 0.05 (71.20 to 1.30) 1.15 (70.16 to 2.46)
B1 0.11 (70.63 to 0.85) 0.48 (70.37 to 1.32) 0.08 (70.64 to 0.80) 0.60 (70.28 to 1.49)
B4 71.10 (72.00 to 70.20)* 70.32 (71.23 to 0.60) 0.21 (70.92 to 1.34) 0.22 (71.02 to 1.46)
BAI 2.66 (72.81 to 8.13) 70.42 (76.97 to 6.13) 70.94 (76.28 to 4.39) 72.36 (79.13 to 4.40)
BDI 4.39 (70.93 to 9.71) 3.35 (72.64 to 9.34) 72.84 (78.36 to 2.69) 70.11 (76.91 to 6.68)
Time budget
Total 9.31 (71.08 to 19.69) 0.23 (711.48 to 11.94) 2.81 (76.56 to 12.18) 6.36 (74.80 to 17.53)
Zero/one 71.54 (75.21 to 2.14) 1.20 (72.94 to 5.35) 71.93 (75.48 to 1.63) 73.51 (77.80 to 0.77)
SOFAS 6.49 (+0.39 to 12.58)* 4.30 (72.79 to 11.39) 3.43 (73.40 to 10.25) 2.98 (75.46 to 11.42)
EuroQol 76.94 (718.85 to 4.98) 77.38 (722.07 to 7.31)
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CBT, cognitive7behavioural therapy; EuroQol, Quality of Life measure; FI, family intervention; PANSS, Positive and
Negative Syndrome Scale; PSYRATS, Psychotic Symptom Rating Scale (A1, hallucination frequency; A8, hallucination distress; B1, delusional conviction; B4, delusional distress);
SOFAS, Social and Occupational Functioning Assessment Scale; TAU, treatment as usual; zero/one, mean number of time periods rated 0 or 1 on time budget.
Table 5 Treatment effect estimates for patients with carers: difference in means (95% CI) between treatment (family intervention
and cognitive–behavioural therapy not distinguished) and treatment as usual
12 months 24 months
PANSS
Total 76.09 (711.89 to 70.29)* 75.62 (711.86 to 0.62)
Positive 71.26 (73.44 to 0.92) 70.28 (72.76 to 2.20)
Negative 72.20 (74.29 to 70.11)* 71.02 (73.29 to 1.25)
General 72.76 (75.76 to 0.24) 73.34 (76.30 to 70.37)*
PSYRATS
A1 70.14 (71.13 to 0.85) 70.41 (71.35 to 0.53)
A8 70.13 (71.32 to 1.07) 1.13 (70.02 to 2.27)
B1 0.42 (70.33 to 1.17) 0.56 (70.23 to 1.36)
B4 0.32 (70.62 to 1.27) 0.21 (70.73 to 1.15)
BAI 1.59 (73.39 to 6.58) 71.38 (76.25 to 3.48)
BDI 3.98 (70.76 to 8.72) 71.94 (76.97 to 3.10)
Time budget total 5.80 (73.72 to 15.33) 4.09 (74.26 to 12.49)
SOFAS 5.68 (+0.20 to 11.15)* 3.28 (72.88 to 9.43)
EuroQol 77.09 (717.80 to 3.63)
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CBT, cognitive7behavioural therapy; EuroQol, Quality of Life measure; FI, family intervention; PANSS, Positive and
Negative Syndrome Scale; PSYRATS, Psychotic Symptom Rating Scale (A1, hallucination frequency; A8, hallucination distress; B1, delusional conviction; B4, delusional distress);
SOFAS, Social and Occupational Functioning Assessment Scale; TAU, treatment as usual; TB, time budget; zero/one, mean number of time periods rated 0 or 1 on time budget.
*P50.05.
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There were 22 serious suicide attempts by trial patients over the
2-year period of their participation: 10 in the no carer pathway
CBT group, 8 in the no carer pathway treatment as usual group
(including the completed suicide), 3 in the carer pathway CBT
group, 1 in the carer family intervention group and none in the
carer treatment as usual group. Violent incidents were recorded
for 45 patients: 22 out of 106 patients in the no carer pathway
CBT group, 17 out of 112 patients in the no carer pathway
treatment as usual group, and 2 in each of the carer pathway
randomisation cells.
Discussion
This trial found no benefits of psychological interventions,
whether CBT or family intervention, for the primary outcomes
of relapse and days in hospital. There were limited benefits for
CBT on the secondary outcomes of improvements in depression,
symptoms and social functioning. For these secondary outcomes,
there is a clear risk of type 1 errors, arising from multiple signifi-
cance testing. We must therefore conclude that generic CBT for
psychosis is not indicated for relapse reduction in unselected
recently relapsed patients.
Methodology
Cognitive–behavioural therapy
The trial, especially with respect to CBT, was methodologically
robust. Randomisation was independent and successful; rates of
follow-up were excellent for primary outcomes and very good
for secondary outcomes; raters were successfully masked; the
assessment of relapse used a clear definition with a protocol
ensuring a valid and reliable assessment by clinicians shown to
have remained masked to allocation; interview assessments for
secondary outcomes were checked for reliability; and the therapy
was conducted by therapists both well-trained and carefully
supervised, whose competence was monitored throughout and
confirmed by independent assessors. The analysis of CBT, by
combining the effects in the no carer and carer pathways, was
adequately powered, as specified in advance in the trial protocol.
Family intervention
The analysis of family intervention was in contrast underpowered,
as was, to a lesser extent, the exploratory analysis of treatment in
those with carers. The primary outcome analysis in the carer
pathway was further compromised by the unexpectedly low rates
of relapse for all groups. This contrasted markedly with the rates
in the no carer pathway and made demonstration of a further
effect on our primary outcomes more challenging. We do not
think this group differed substantially in terms of time in contact
from other studies of carers. Although the minimum contact
requirement was 10 h per week, in practice this was higher, with
a total mean contact time of 39 h per week,48 and, as shown in
online Table DS3, the means for the randomised groups range
from 34–44 h a week. We do know that the carers in this study
had predominantly low ratings of EE.48 This may reflect secular
changes in carers’ knowledge and attitudes, or the largely subur-
ban and rural residence of patients who had carers. This suggests
that for unselected groups of carers in 21st-century Britain, family
intervention may not improve outcomes further than a good
standard of treatment as usual. Where criticism was present, it
was reduced in those given family intervention. However, our
study has too little power for robust conclusions about family
intervention.
General outcomes
The outcomes for this sample of recently relapsed people with
psychosis were disappointing, regardless of treatment allocation.
Particularly in the no carer pathway, full remission from the index
relapse was relatively infrequent, with high levels of persisting
symptoms. Despite some improvement, the group remained very
symptomatic at 24 months. The failure of psychological inter-
ventions substantially to affect outcome should not lead us to dis-
regard the poor outcome of standard care, including medication,
delivered to this group.
People with carers
People with carers fared rather better, both in general and in re-
sponse to treatment. Those in the carer pathway allocated to
CBT made improvements in delusional distress and social
functioning. Furthermore, our exploratory analyses of treatment
in the total group of those with carers revealed consistent indica-
tions of a positive benefit on general and negative symptoms and
social functioning, whether from CBT or family intervention.
These results suggest that having a carer may improve the response
to a psychological intervention. This has not been noted elsewhere
in the literature. Other studies of CBT in psychosis have not
distinguished participants according to whether they have carers.
All studies of family intervention, of course, involve patients with
carers. We did not anticipate this finding, and cannot explain it,
since the effect of having a carer may be confounded by other vari-
ables. In the present study, those with carers were more likely to
live in less urbanised areas and were more likely to be White,
and the carer effect on treatment might be related to these or other
unknown factors; however, our data, being limited in range, do
not permit further investigation. The only other published exam-
ple of a study of psychological intervention to have employed se-
parate pathways for individuals living with families and those who
were not49,50 did not find consistent effects related to carers. The
more recent literature on the effects of social environments, both
proximal and distal,51 gives credence to the positive effect of social
support and the detrimental effect of social adversity, and suggests
this might be particularly relevant to the development and main-
tenance of positive symptoms of psychosis.52,53 The effect of carers
both on symptoms and on response to psychological interventions
warrants further investigation.
The sample
We consider that there are two main aspects of the study that
might explain our largely negative findings for CBT: factors
associated with the sample and the nature of the therapy. First,
the sample recruited into this study was drawn from consecutive
series of acutely ill patients who had experienced a recent relapse.
This strategy was deliberate and was intended to address the
public health question of the benefit of treatment for an
unselected population, following the recommendation of the
NICE guidelines for schizophrenia.16 Clearly, this population
differs from patients in a stable phase of illness with distressing
persistent symptoms studied in many earlier studies of CBT and
for whom moderately positive effects have consistently been
demonstrated.8,9 Our sample was very mixed. Many had clearly
relapsed in response to ceasing medication and they thus represent
a medication-sensitive, if not a medication-adherent, group.
Inevitably, some had a rapid response to hospitalisation and
medication; by the time they had started therapy, this group
reported few problems. Some had low distress levels, despite
persisting symptoms, and some had very limited interest in having
psychological therapy. This last group might include some who
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have an avoidant (‘sealing over’) recovery style and are particularly
fragile.54
The therapy
Second, was the therapy right? There is no doubt that it was
competently delivered. However, therapists reported that it was
sometimes difficult, in the absence of symptoms or of distress,
to maintain a clear focus on the positive psychotic symptoms
for which generic CBT for psychosis is best established. Instead,
therapists covered a wide range of self-reported problems and
symptoms, adopting a general approach to emotional distress.
Nevertheless, the CBT as delivered did have a particular focus
on relapse interventions, as shown recently in a content analysis
of therapy tapes.55 The therapy did not influence the predicted
mediators of change, such as specific core beliefs or reasoning.35,36
It should be noted that the failure of treatment in the context of a
failure to change hypothesised mediators leaves the hypothesis of
proposed mediation unrefuted. Thus, it proved difficult to deliver
a therapy sufficiently targeted on, or effective with, the key factors
influencing psychotic symptom maintenance or recurrence.
Rather, the indications were that such benefits as occurred were
not specific to psychotic symptoms, being more general effects
on depression, emotional well-being and functioning. We
conclude that generic CBT for psychosis should continue to be
offered for distressing and persistent positive symptoms, rather
than be applied to relapse prevention. Future development of
CBT should be directed at targeting and improving the key cog-
nitive and emotional processes identified in theoretical models
of distressing symptoms and relapse.13,51,56 The recent successful
trial of CBT for command hallucinations, which aims to reduce
distress by changing appraisals of these particular experiences, is
a good example of this approach.14
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Data supplement
Table DS1 Demographic characteristics of patients with and without carers
No carer pathway Carer pathway
TAU
(n=112)
CBT
(n=106)
TAU
(n=28)
CBT
(n=27)
FI
(n=28)
Mean age: years (s.d.) 37.1 (10.9) 39.1 (10.3) 35.6 (11.2) 38.6 (12.2) 35.0 (12.3)
Gender (n)
Male
Female
77
35
74
32
19
9
21
6
20
8
Ethnicity (n)
White
Black Caribbean
Black African
Black other
Indian
Other
82
7
14
4
0
5
65
13
12
3
5
8
23
1
0
0
0
4
23
1
1
0
0
2
24
1
1
0
0
2
Employment (n)
Employed
Employed part time
Voluntary employment
Unemployed
Student
Retired
Housewife/husband
Unknown
4
4
1
97
5
1
0
0
4
2
7
87
3
0
2
1
4
0
0
20
3
1
0
0
1
0
0
25
0
1
0
0
3
3
2
20
0
0
0
0
Marital status (n)
Single
Married
Divorced/separated
Widowed
Unknown
89
2
18
1
2
77
7
21
1
0
18
6
3
0
1
14
9
3
1
0
20
7
1
0
0
CBT, cognitive–behavioural therapy; FI, family intervention; TAU, treatment as usual.
Table DS2 Clinical characteristics of patients with and without carers
No carer pathway Carer pathway
TAU
(n=112)
CBT
(n=106)
TAU
(n=28)
CBT
(n=27)
FI
(n=28)
Diagnosis (n)
Schizophrenia
Schizo-affective disorder
Delusional disorder
95
17
0
92
10
4
22
6
0
25
2
0
23
5
0
In-patient (n)
Out-patient (n)
78
34
76
30
18
10
16
11
16
12
Mean length of illness in years (s.d.) 9.9 (8.7) 10.9 (8.1) 10.5 (8.6) 10.9 (9.7) 13.3 (11.8)
Mean number of admissions (s.d.) 4.4 (4.4) 5.0 (5.6) 4.6 (5.5) 3.4 (3.2) 6.5 (9.2)
History of violence (n)
No
Yes
79
30
66
35
23
5
20
7
21
7
History of suicide or self-harm (n)
No
Yes
65
42
65
35
15
13
16
11
14
12
CBT, cognitive–behavioural therapy; FI, family intervention; TAU, treatment as usual.
2Table DS3 Carer characteristics
TAU CBT FI
Mean age: years (s.d.) 54.5 (11.6); n=24 48.3 (11.8); n=23 55.2 (15.0); n=23
Gender (n)
Male
Female
10
18
5
20
9
19
Ethnicity (n)
White
Black Caribbean
Black African
Black-other
Indian
Other
23
1
0
0
0
3
23
0
1
0
0
1
24
1
1
0
0
1
Employment (n)
Employed
Employed part time
Voluntary employment
Unemployed
Student
Retired
Housewife/husband
Unknown
9
4
0
7
0
5
2
1
6
3
0
13
1
0
1
3
5
3
1
9
0
3
5
1
Marital status (n)
Single
Married
Divorced/separated
Widowed
Cohabiting
Unknown
3
14
3
4
3
1
3
15
4
2
0
3
3
18
3
3
0
1
Relationship to patient (n)
Parent
Spouse/partner
Sibling
Son/daughter
Other
14
11
2
0
1
9
11
4
1
0
18
8
1
0
0
Mean amount of face-to-face contact with patient per week, hours (s.d.) 44.3 (25.2); n=24 38.6 (22.7); n=25 34.0 (23.2); n=22
EE rating (n)
High
Low
10
18
7
19
12
16
Mean GHQ total score (s.d.) 52.2 (11.6); n=27 55.4 (16.4); n=20 56.2 (16.0); n=26
CBT, cognitive–behavioural therapy; EE, expressed emotion; FI, family intervention; GHQ, General health Questionnaire; TAU, treatment as usual.
3Table DS4 Mean scores for psychotic symptom measures for each treatment group for patients with and without carers
No carer pathway Carer pathway
TAU CBT TAU CBT FI
n Mean s.d. n Mean s.d. n Mean s.d. n Mean s.d. n Mean s.d.
PANSS total
Baseline 112 66.26 15.91 106 62.32 13.49 28 64.11 15.28 27 66.89 14.26 28 70.93 13.36
12 months 90 59.66 17.27 90 57.63 15.21 23 58.35 14.03 21 54.09 12.49 24 57.46 15.53
24 months 85 57.32 15.43 87 56.68 12.98 24 56.04 18.02 22 54.41 16.70 20 55.50 15.26
PANSS positive
Baseline 112 19.04 5.20 106 17.99 5.41 28 16.50 5.33 27 17.11 6.01 28 17.86 4.54
12 months 90 16.49 6.47 90 15.39 6.37 23 15.09 5.23 21 13.95 5.69 24 14.54 5.24
24 months 85 15.32 6.01 87 16.02 6.44 25 14.24 6.11 22 14.23 6.41 21 16.52 6.90
PANSS negative
Baseline 112 12.96 6.65 106 11.79 4.81 28 13.82 4.89 27 15.67 5.88 28 17.25 6.59
12 months 90 12.62 6.32 90 12.06 4.92 23 13.26 5.58 21 12.33 4.94 24 13.38 5.81
24 months 85 11.91 5.21 87 11.64 4.83 25 11.88 5.19 22 12.18 4.38 21 12.95 8.09
PANSS general
Baseline 112 34.26 7.96 106 32.54 7.40 28 33.79 9.33 27 34.11 7.08 28 35.82 6.24
12 months 90 30.54 8.17 90 30.19 7.78 23 30.00 7.45 21 27.81 6.76 24 29.54 7.60
24 months 85 30.09 7.92 87 29.01 6.09 24 29.54 9.45 22 28.00 8.42 20 28.25 6.56
PSYRATS A1
Baselinea 66 2.39 1.02 50 2.36 1.06 14 2.00 1.18 11 2.91 1.04 23 2.35 1.11
12 monthsa 50 1.28 1.51 40 1.40 1.48 10 2.40 1.26 10 1.50 1.78 19 1.63 1.61
24 monthsa 48 1.35 1.44 39 1.18 1.32 12 1.92 1.56 9 1.89 1.69 16 1.50 1.46
PSYRATS A8
Baselinea 65 2.58 1.32 50 2.64 1.47 14 2.64 1.34 11 2.82 1.08 22 2.73 1.24
12 monthsa 50 1.30 1.61 40 1.35 1.72 10 2.30 1.49 10 1.50 1.72 19 1.53 1.74
24 monthsa 48 1.17 1.58 39 1.44 1.64 12 1.50 1.78 9 0.78 1.30 16 2.00 1.79
PSYRATS B1
Baselineb 90 2.80 1.01 84 2.61 1.04 20 2.35 0.93 21 2.29 1.01 22 2.68 0.95
12 monthsb 69 1.70 1.44 69 1.54 1.29 16 1.00 1.03 16 1.68 1.40 19 1.84 1.21
24 monthsb 66 1.45 1.27 67 1.60 1.34 18 1.00 1.24 18 1.11 1.08 16 1.63 1.59
PSYRATS B4
Baselineb 89 2.73 1.40 84 2.80 1.27 20 2.80 1.20 21 2.71 1.23 22 3.00 1.15
12 monthsb 70 1.80 1.78 69 1.84 1.75 16 2.13 1.89 16 1.50 1.55 19 2.32 1.57
24 monthsb 65 1.75 1.66 67 1.61 1.71 18 1.50 1.76 18 1.61 1.72 16 1.63 1.68
CBT, cognitive–behavioural therapy; FI, family intervention; PANSS, Positive and Negative Syndrome Scale; PSYRATS, Psychotic Symptom Rating Scale (A1, hallucination frequency; A8, hallucination distress; B1, delusional conviction; B4, delusional distress);
TAU, treatment as usual.
a. If PYSYRATS A1 >0 at baseline.
b. If PYSYRATS B1 >0 at baseline.
4Table DS5 Mean scores for other symptoms and social function scores in patients with and without carers
No carer pathway Carer pathway
TAU CBT TAU CBT FI
n Mean s.d. n Mean s.d. n Mean s.d. n Mean s.d. n Mean s.d.
BDI
Baseline 108 20.94 13.66 103 21.53 12.12 28 20.57 13.33 27 24.89 12.56 27 28.96 13.92
12 months 83 17.52 13.90 83 15.66 13.07 21 12.05 10.66 20 18.75 14.33 23 20.87 13.32
24 months 77 17.18 13.10 78 15.19 11.63 24 16.04 14.82 22 15.54 10.91 18 21.39 13.87
BAI
Baseline 101 19.95 14.79 97 19.31 13.60 27 16.07 12.18 25 18.44 11.90 26 28.81 17.63
12 months 80 14.19 12.42 75 15.31 12.53 21 10.33 8.91 19 15.53 12.86 22 16.32 14.95
24 months 76 15.17 12.80 76 16.58 14.40 22 14.68 9.79 22 15.82 14.67 18 16.41 12.79
Time budget total
Baseline 101 53.36 21.76 97 47.52 15.59 25 51.32 20.43 25 46.16 22.72 27 49.11 21.44
12 months 87 54.97 23.06 77 57.26 19.12 19 51.53 25.76 19 62.16 28.22 22 50.14 16.38
24 months 78 56.41 23.38 82 56.45 18.37 24 53.54 23.70 21 59.67 18.10 19 59.79 20.03
Time budget zero/one
Baseline 101 10.96 8.17 97 12.39 7.08 25 13.16 7.37 25 13.24 9.47 27 12.81 8.15
12 months 87 9.83 8.38 78 8.79 7.38 19 12.32 9.57 19 8.89 7.76 22 12.18 6.45
24 months 78 9.94 9.14 82 8.67 7.41 24 12.00 8.97 21 8.29 7.06 19 8.58 8.44
SOFAS
Baseline 112 51.84 15.29 106 49.44 12.82 28 55.21 14.77 27 51.07 15.66 28 52.11 15.89
12 months 90 51.88 15.47 90 52.02 15.92 23 53.26 14.94 21 60.91 13.83 24 55.58 13.09
24 months 85 52.07 15.96 85 53.04 13.31 25 57.04 16.83 22 59.73 14.53 19 58.37 20.26
EuroQol , 24 months 74 62.68 20.54 71 60.17 22.99 24 63.67 18.49 21 52.52 22.76 16 54.38 29.28
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CBT, cognitive–behavioural therapy; FI, family intervention; EuroQol, Quality of Life measure; SOFAS, Social and Occupational Functioning Assessment Scale; TAU, treatment as usual; zero/one, mean
number of time periods rated 0 or 1 on time budget.
5Table DS6 Selected change scores in patients with carers
No carer pathway Carer pathway
TAU CBT TAU CBT FI
n Mean s.d. n Mean s.d. n Mean s.d. n Mean s.d. n Mean s.d.
PANSS total
0–12 months 13 2.85 19.84 15 11.27 17.44 23 2.52 15.11 21 10.57 11.29 24 14.42 16.22
0–24 months 12 5.00 8.54 15 14.67 18.23 24 5.71 16.75 22 11.05 13.94 20 15.05 17.39
PANSS general
0–12 months 13 0.92 10.51 15 5.33 7.61 23 1.74 8.89 21 5.00 6.39 24 6.63 8.77
0–24 months 12 1.83 5.11 15 7.33 8.64 24 2.63 8.21 22 5.32 7.75 20 7.75 7.38
BDI
0–12 months 10 10.7 11.78 12 5.33 11.91 21 6.95 7.49 20 4.85 13.82 23 8.26 12.30
0–24 months 11 5.45 11.02 11 7.64 13.84 24 3.42 15.34 22 8.55 11.03 18 7.61 11.29
BDI, Beck Depression Inventory; CBT, cognitive–behavioural therapy; FI, family intervention; PANSS, Positive and Negative Syndrome Scale; TAU, treatment as usual.
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